Scrip
>>Drug Pricing

Pharma Strategizes On Drug Pricing On Day One Of J.P. Morgan

Jan 10 2017

• By Jessica Merrill

Listen to this article

Drug pricing was a big theme at the industry’s biggest business meeting of the year, and it’s poised to remain one throughout 2017. While drug makers acknowledged issues, they mostly defended their pricing strategies.

US pennies

Drug pricing was a reoccurring theme on the opening day of the J.P. Morgan Healthcare conference in San Francisco Jan. 9., with pharmaceutical investors increasingly concerned about the sustainability of high drug pricing in the US. With payer pushback on drug prices intensifying and many consumers and regulators outraged over high drug prices, the issue is expected to be a dominant one in 2017 that could clip sector growth.

The question of drug pricing and pricing power came up in almost every big biopharma presentation, and while executives openly...

More from Drug Pricing

How A New Healthcare Dialogue Is Driving Market Access In Mexico
Nov 06 2025
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2
Oct 14 2025
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
Sponsored By
Nancy Tests SPARC-931 Part 8
This is a short description. This is a short description.
As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS
Mar 10 2025
• By Mandy Jackson
Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.

More from Scrip

sponsored
Sponsored by :
Clinical Trial Complexity Is Reshaping Evidence Collection Clinical trial innovation has historical
As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.
EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance
Jul 15 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone
Jun 18 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.